8-K/A: Vivos Inc. Strengthens Leadership with Key Executive Appointments

Vivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, bolstering its leadership in targeted cancer therapies.

Summary

• Vivos Inc. appointed Brad Allan Weeks as President, effective September 1, 2025, with a term ending December 31, 2027, extendable by mutual agreement.
• Mr. Weeks will receive an annual base salary of $192,000 and a monthly grant of $3,000 in common stock, based on the closing price at the end of each fiscal quarter.
• David J. Swanberg was appointed Chief Operating Officer, effective September 1, 2025, with a term ending December 31, 2028, also extendable by mutual agreement.
• Mr. Swanberg will receive a consulting rate of $12,000 per month and a monthly grant of $3,000 in common stock, based on the closing price at the end of each fiscal quarter.
• The filing is an Amendment No. 1 to a Current Report on Form 8-K, filed solely to correct typographical errors in the section detailing Mr. Swanberg's appointment.

Sentiment

Score: 8

Explanation: The appointments of highly experienced executives in key leadership roles, particularly with backgrounds directly relevant to the company's specialized field of targeted cancer therapies and medical devices, are a strong positive signal for Vivos Inc.'s strategic direction and operational capabilities. The amendment itself is minor, correcting typographical errors, and does not detract from the positive impact of the executive hires.

Positives

• Strengthens executive leadership with highly experienced professionals in the medical device, biotechnology, and radiochemical sectors.
• Brad Allan Weeks brings expertise in business development, team expansion, and strategic partnerships, including international collaborations, crucial for growth.
• David J. Swanberg offers over 35 years of experience in radiochemical processing, medical isotope production, regulatory affairs, and product development, including co-founding IsoRay Medical Inc.
• Mr. Swanberg's prior role as Chief Technical Manager for Vivos Inc. since 2017 ensures continuity and deep understanding of the company's product development and regulatory processes.
• The appointments are expected to play a pivotal role in driving Vivos Inc.'s growth in targeted cancer therapies, aiming for safer and more effective radionuclide treatments.

Future Outlook

The appointments are expected to play a pivotal role in Vivos Inc.'s business development, team expansion, and strategic partnerships, contributing to the company's growth in targeted cancer therapies that deliver radioactive agents directly to tumors while minimizing damage to healthy tissue. The terms for both executives are extendable by mutual written agreement, indicating potential long-term leadership stability.

Management Comments

• Brad Allan Weeks is a seasoned leader with extensive experience in the medical device and biotechnology sectors.
• As President, Brad plays a pivotal role in business development, team expansion, and strategic partnerships, contributing to the Company's growth in targeted cancer therapies.
• Brad has built a distinguished career in healthcare innovation, holding leadership positions at organizations focused on advancing medical technologies and patient outcomes.
• Brad is actively involved in promoting the Company's mission to revolutionize oncology through safer, more effective radionuclide therapies.

Industry Context

These appointments reflect a strategic move by Vivos Inc. to strengthen its leadership in the competitive and rapidly evolving targeted cancer therapy and medical device sectors. The focus on radionuclide therapies aligns with a growing trend towards precision oncology, aiming to deliver more effective treatments with reduced side effects. The extensive experience of both executives in medical devices, biotechnology, and radiochemical processing positions Vivos Inc. to capitalize on advancements in these specialized fields and navigate complex regulatory environments.

Comparison to Industry Standards

• David J. Swanberg's background includes co-founding IsoRay Medical Inc., a company known for its Cs-131 brachytherapy seed product development. This experience is directly comparable to the regulatory and product development challenges faced by companies in the radionuclide therapy space, demonstrating a proven track record in bringing specialized medical technologies to market.
• His participation in over $30.0 million in capital financing rounds at IsoRay Medical Inc. demonstrates significant experience in securing funding, a critical aspect for growth-stage biotechnology companies operating in capital-intensive sectors.
• Brad Allan Weeks' experience in medical device and biotechnology sectors, including forging international collaborations, aligns with the global expansion strategies often pursued by innovative healthcare companies seeking to broaden their market reach and patient impact.

Management Changes

Corporate Governance

Related Party Transactions

• Explicitly states that neither Mr. Weeks nor Mr. Swanberg are participants in any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K, except for their disclosed employment and consulting agreements.

Stakeholder Impact

• **Shareholders:** Potential positive impact due to strengthened leadership, which could lead to improved strategic execution, operational efficiency, and ultimately, enhanced shareholder value.
• **Employees:** New leadership may bring changes in organizational structure or strategic direction, potentially impacting roles and opportunities, but also offering new growth avenues.
• **Customers/Patients:** Enhanced leadership in product development and regulatory affairs could accelerate the delivery of safer, more effective radionuclide therapies, improving patient outcomes.
• **Suppliers/Partners:** New leadership may influence strategic partnerships and supply chain relationships, potentially leading to new collaborations or optimized existing ones.

Next Steps

• Continued business development, team expansion, and strategic partnerships under the new leadership.
• Further growth and innovation in targeted cancer therapies.
• Potential extension of executive terms beyond December 2027 and December 2028, respectively, by mutual agreement.

Key Dates

Recommendation

The appointment of two highly experienced executives, Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, significantly strengthens Vivos Inc.'s leadership team. Both individuals bring extensive and directly relevant expertise in medical devices, biotechnology, radiochemical processing, and regulatory affairs, which are critical for the company's focus on targeted cancer therapies. Mr. Swanberg's prior role as Chief Technical Manager and his experience co-founding IsoRay Medical Inc. provide a strong foundation for operational excellence and product development. These strategic hires are expected to drive business development, expand market reach, and enhance the company's ability to navigate regulatory landscapes, positioning Vivos Inc. for future growth and potentially increasing shareholder value. The compensation packages, including stock grants, align executive incentives with shareholder interests.

Keywords

Vivos Inc., executive appointments, President, Chief Operating Officer, Brad Allan Weeks, David J. Swanberg, medical device, biotechnology, radiochemical processing, cancer therapies, IsoPet, RadioGel, corporate governance, SEC filing, 8-K/A